1. Planned filings 2012 to  2016
2012 2013 2014 2015  2016
ACZ885 AFQ056 LCQ908 BKM120 ATI355 LGX818
SJIA1 Fragile X syndrome Metabolic diseases Solid tumors Spinal cord injury Solid tumors
Lucentis AIN457 LCZ696 QGE031 AUY922 MEK162
Pathological myopia Psoriasis Heart failure Allergic diseases Solid tumors Solid tumors
QTI571 DEB0253 LDE225 Afinitor® BAF312 NIC002
Pulm. arterial hyperten. HCV infection Basal cell carcinoma Lymphoma Multiple sclerosis Smoking cessation
SOM230 LBH589 PKC412 QMF149 BCT197 QAW039
Acromegaly Multiple Myeloma AML6 COPD2 COPD2 Asthma
QVA149 RLX030 AFQ056 QMF149 BEZ235 ACZ885
COPD2 Acute heart failure PD-LID7 Asthma Solid tumors Diabetes
TKI258 AIN457 Tekturna ® BGS649 ACZ885
Renal cell carcinoma Arthritides (RA,AS,PsA)8 Heart failure11 OHH13 Sec. Prev. CV events15
Afinitor® Gilenya ® Afinitor® BYL719 AIN457
HER2+ Breast cancer CIDP9 GI/Lung NET12 Solid tumors Multiple sclerosis
Afinitor® INC424 BYM338 Lucentis
HCC4 Polycythemia vera sIBM14 CNV and ME16
Xolair LCZ696 CAD106 LDE225
CIU5 Hypertension Alzheimer’s Solid Tumors
PKC412 HCD122 Tekturna ®
ASM10 Hemat. tumors CV events in elderly
1 Systemic onset juvenile idiopathic arthritis
2 Chronic obstructive pulmonary disease Tasigna® LCI699 TKI258
3 On clinical hold cKIT Melanoma Cushing’s Solid tumors
4 Hepatocellular carcinoma
5 Chronic idiopathic urticaria
6
LGT209
Acute myeloid leukemia 12 Hypercholesterolemia
7 Parkinson’s disease L-dopa induced Neuroendocrine tumors New molecule
dyskinesia 13 Obese hypogonadotropic hypogonadism
8 Rheumatoid arthritis, 14 Sporadic inclusion body myositis
LFF571
Ankylosing spondylitis and psoriatic 15 Cl. difficile infections
Secondary prevention of cardiovascular events New
arthritis 16 Choroidal neovascularization (CNV) and
9 Chronic inflammatory demyelinating Indication
macular edema (ME) secondary to conditions
polyneuropathy other than age related macular degeneration,
10 Aggressive systemic mastocytosis diabetic macular edema, Retinal vein New formulation
11 Reduction of CV death/hospitalization in chronic occlusion and pathologic myopia
heart failure patients
51 | Novartis Q1 2012 Results | April 24, 2012 | Novartis Investor Presentation